Corbus Pharmaceuticals Holdings, Inc.

corbuspharma.com

What Do They Do?

Develops clinical-stage medicines for people with cancer and obesity, including targeted cancer therapies and an oral obesity treatment.

How Do They Make Money?

Corbus has not generated revenue from product sales; it would need to complete development and obtain regulatory approval before selling its drug candidates. The reported revenue is not described as product-sale revenue.

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $78.5M in FY2025.

Operating income, FY2025

−1543% of revenue

▲ +75% (Loss) vs FY2024 (−$48.7M, −772%)

Net income, FY2025

−1420% of revenue

▲ +95% (Loss) vs FY2024 (−$40.2M, −637%)

Free cash flow, FY2025

−1166% of revenue

▲ +54% (Loss) vs FY2024 (−$41.8M, −662%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▼ −11%; vs $1.3M in Q2 FY2025
Net income: ▲ +98% (Loss); vs −$17.7M in Q2 FY2025

Sep 14, 2026 CRB-913 trial reported weight loss across all tested doses The 60 mg dose produced mean weight loss of 5% at 12 weeks.
Aug 6, 2026 CRB-701 cleared to proceed with a registrational cancer study The company said it expects to begin enrollment in TEMPO-1 in September 2026.

Growing. Revenue grew 6.3x in 4 years, from $881.7K in FY2021 to $5.5M in FY2025, about 58% a year.

Who Do They Compete With?

Competes with Bicycle Therapeutics, Mabwell, Pfizer, Bicara Therapeutics, Genmab, Johnson and Johnson, Novo Nordisk, Skye Bioscience, AstraZeneca, Lilly, Structure Therapeutics, and Viking Therapeutics

Comments